'Industrializing the production of cells': Another iPSC player joins the quest for off-the-shelf cell therapies

Nicole DeFeudis

Editor

Scientists have been after the “Holy Grail” of cell therapy — an off-the-shelf product — for years. Notch Therapeutics is now joining the quest with a tech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'Industrializing the production of cells': Another iPSC player joins the quest for off-the-shelf cell therapies

Nicole DeFeudis

Editor

Sign up to read this article for free.

Q&A: GSK CSO Tony Wood on staying out of obesity, 'careful' cancer ambitions, and AI's future in R&D

FDA approves reformulated Covid boosters for fall season

FDA to host adcomm on PD-L1 as a predictive biomarker for checkpoint inhibitors

Autoimmune biotech Zenas files for IPO amid summer lull for public debuts

Versant and Novartis build 'Chinook 2.0' for RNA therapies in kidney diseases

BioMarin shakes up executive team, tapping notable dealmaker James Sabry

'In­dus­tri­al­iz­ing the pro­duc­tion of cell­s': An­oth­er iP­SC play­er joins the quest for off-the-shelf cell ther­a­pies

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Q&A: GSK CSO Tony Wood on stay­ing out of obe­si­ty, 'care­ful' can­cer am­bi­tions, and AI's fu­ture in R&D

FDA ap­proves re­for­mu­lat­ed Covid boost­ers for fall sea­son

FDA to host ad­comm on PD-L1 as a pre­dic­tive bio­mark­er for check­point in­hibitors

Au­toim­mune biotech Zenas files for IPO amid sum­mer lull for pub­lic de­buts

Ver­sant and No­var­tis build 'Chi­nook 2.0' for RNA ther­a­pies in kid­ney dis­eases

Bio­Marin shakes up ex­ec­u­tive team, tap­ping no­table deal­mak­er James Sabry

'Industrializing the production of cells': Another iPSC player joins the quest for off-the-shelf cell therapies

Q&A: GSK CSO Tony Wood on staying out of obesity, 'careful' cancer ambitions, and AI's future in R&D

FDA approves reformulated Covid boosters for fall season

FDA to host adcomm on PD-L1 as a predictive biomarker for checkpoint inhibitors

Autoimmune biotech Zenas files for IPO amid summer lull for public debuts

Versant and Novartis build 'Chinook 2.0' for RNA therapies in kidney diseases

BioMarin shakes up executive team, tapping notable dealmaker James Sabry